Background
Gastrointestinal stromal tumors (GISTs) are the most common sarcoma of the gastrointestinal tract, occurring mostly in the muscular wall of the stomach or small bowel, where it is felt to arise from the interstitial cells of Cajal or similar cells [
1,
2]. The primary treatment for GIST is surgical excision, but a significant number of cases recur [
3,
4]. Adjuvant imatinib, a tyrosine kinase inhibitor, is useful in select cases of GIST based on risk of recurrence [
5‐
8]. At present, the risk of recurrence is determined based on tumor size, mitotic rate, tumor site, and tumor rupture [
1,
5,
8‐
13], as for example in the Miettinen risk score [
11], but more accurate predictors would be useful to better direct therapy.
While most GISTs have mutations in the KIT gene, mutations in the platelet derived growth factor receptor alpha (PDGFRA) gene are also common [
1,
2,
5,
8,
14]. In a small percentage of GISTs, mutations in other genes such as BRAF, succinate dehydrogenase (SDH), or neurofibromatosis (NF) may occur [
1,
5,
15‐
20]. The type of KIT or PDGFRA mutation may affect the recurrence rate as well as response to imatinib [
5,
8]. Despite the key role of activating mutations of KIT or PDGFRA, GIST biology is also dependent upon other genetic changes [
1]. Cases of KIT-mutant GIST have been reported that present with coexisting downstream mutations [
5,
8,
21,
22].
Gene expression patterns have been used to predict the development of metastases in soft tissue sarcoma [
23‐
26]. Differences in the gene expression profiles of GISTs with different KIT- or PDGFRA-mutant tumors have been reported [
27,
28], and several recent studies have explored the use of gene expression patterns to predict recurrence rate of GIST [
29‐
35].
In previously published studies using various biochemical pathways, we derived gene expression profiles that identified two subgroups of aggressive fibromatosis (AF-gene set), ovarian carcinomas (OVCA-gene set), and clear cell renal cell carcinomas (RCC-gene set) [
36‐
39]. We previously used a gene set derived from these three studies to separate 73 high grade soft tissue sarcoma into 2 or 4 groups with different propensities of metastasis [
25]. In an independent study, these gene sets were used to separate 309 high-grade soft tissue sarcoma into 2 or 4 groups with different propensity of metastasis [
26].
In the present study, we utilized our three gene sets to examine a group of 60 GISTs using Agilent chip based expression profiling [
33]. These gene sets successfully separated the GIST samples into subsets with different probabilities of developing disease recurrence, and may be useful to better predict who would benefit from adjuvant imatinib.
Discussion
The biologic heterogeneity of GISTs, as with other soft tissue sarcomas, introduces complexities in deciding optimal treatment. This study used hierarchical clustering with gene sets derived from earlier studies of various biochemical pathways in aggressive fibromatosis, renal cell carcinoma, and ovarian carcinoma [
36‐
39,
43] to examine 60 GIST samples using Agilent chip expression profiling. The analyses separated the GIST samples into at least two groups with different probabilities of developing metastatic disease. Although the gene sets were derived using biochemical pathways, we did not observe simple differences in biochemical pathways between the groups; possibly with a larger sample set, more detailed biochemical differences will become evident. Our data suggest that appreciation of these GIST subsets with distinct clinical behavior could be used to stratify GIST patients in clinical trials and in patient management. Miettinen risk group classification also identified distinct risk groups in our 60 GIST cases. In particular, our analysis also identified subsets of Miettinen high- and intermediate-risk samples that different in the risk of metastasis. When the high- and intermediate-risk GIST samples were examined without the low- and very low-risk samples, the individual AF-gene set, OVCA-gene set, RCC-gene set, and the combined gene set were associated with the time to development of metastasis. This finding suggests that further characterization of recurrence risk among samples classified as high- or intermediate-risk is possible. Furthermore, these results validate the potential role of the use of these gene sets in predicting the behavior of heterogeneous tumor sets.
These gene sets have also been shown to separate sets of soft tissue sarcoma samples into groups with different metastatic behavior [
25,
26]. A gene set of 67 genes involved in mitosis and control of chromosome integrity, termed the complexity index in sarcomas (CINSARC), also predicts metastasis outcome in non-translocation dependent soft tissue sarcomas [
23]. Both the gene sets used here and the CINSARC [
23,
33] gene set identified subsets of the GIST samples that differed in time to recurrence. These data support the potential use of these gene sets to predict biological behavior in GIST as well as other soft tissue sarcomas. Only 11 of the 67 genes in the CINSARC gene set were also present in our pooled gene set.
Other methods of examining genetic heterogeneity may also be helpful. A recent study found that chromosomal changes detected by comparative genomic hybridization (CGH) were predictive of GIST outcome [
33]. This study, as well as a second study, also found that a “genomic index” calculated from the number of chromosomal alterations (segmental gains and losses), and number of chromosomes involved was a strong predictor of recurrence as well [
33,
44]. Another study using array-based analysis of gene copy number separated 42 GISTs into 4 groups with different survival rates [
35].
Conclusions
Gene expression profiles may provide a useful technique to better predict long-term outcomes after surgery in patients with GIST and other sarcomas. Such information could be used to restrict the use of adjuvant therapy and reduce heterogeneity among groups in clinical trials. Due to the limited sample size of our study, we examined the identification of only two subsets of the GIST sample set with different metastatic propensity. The ability to detect multiple subgroups is highly dependent on the number of samples and the distribution of samples among the various groups. With larger sample sets, it may be possible to further refine classification and identify clinically useful heterogeneity. In addition, although gene expression analysis may provide a useful indicator of long-term outcomes, it should be used in combination with standard prognostic factors in order to have maximum predictive value [
8]. For example, in this study, further characterization of recurrence risk among samples classified as high-or intermediate-risk was possible. These results also validate the potential role of the use of these gene sets in predicting the behavior of heterogeneous tumor sets. Several different gene sets appear to separate the samples into 2 groups with different behavior.
Authors’ contributions
KMS, KG, APNS, WX participated in study design, data analysis, and helped draft the manuscript. JK participated in data analysis, and helped draft the manuscript. All authors read and approved the final manuscript.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (
http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (
http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.